Fig. 6.

Kaplan–Meier curve showing the estimated probability of maintaining overall success at 3 years following gel stent implantation in the effectiveness^a OAG population with both IOP measurement and number of topical IOP‐lowering medications recorded at baseline (n = 163^b) (A) and patient subgroup with POAG (n = 120) (B). Overall success was defined as a primary eye achieving complete success (≥20% IOP reduction from medicated baseline without SSI, clinical hypotony [as defined in the Outcomes section] or topical IOP‐lowering medications) or qualified success (≥20% IOP reduction from medicated baseline without SSI or clinical hypotony, while remaining on the same number or fewer topical IOP‐lowering medications), excluding eyes that required more IOP‐lowering medications postimplantation, compared with baseline. Failing to achieve the overall success at any time during postimplantation follow‐up was considered as failure. Primary eyes were considered as censored in the Kaplan–Meier analysis when their follow‐up period (including completing the study) ended before they failed. ^aAll effectiveness analyses included one eye per patient; in cases of bilateral implantation, only the first implanted eye was analysed. ^bThis analysis was based on the primary outcome measures and thus excluded 11 patients who did not have both IOP and IOP‐lowering medication count data at baseline. IOP = intraocular pressure, OAG = open‐angle glaucoma, phaco = phacoemulsification with intraocular lens placement, POAG = primary open‐angle glaucoma, SSI = glaucoma‐related secondary surgical intervention.